|
|
|
|
| LEADER |
00000cam a2200000 c 4500 |
| 001 |
1844450724 |
| 003 |
DE-627 |
| 005 |
20230809214035.0 |
| 007 |
tu |
| 008 |
230503s2022 gw ||||| m 00| ||eng c |
| 035 |
|
|
|a (DE-627)1844450724
|
| 035 |
|
|
|a (DE-599)KXP1844450724
|
| 035 |
|
|
|a (OCoLC)1378104480
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rda
|
| 041 |
|
|
|a eng
|
| 044 |
|
|
|c XA-DE-BW
|
| 082 |
0 |
4 |
|a 616.994
|q DE-101
|
| 082 |
0 |
4 |
|a 610
|a 570
|q DE-101
|
| 084 |
|
|
|a 33
|2 sdnb
|
| 084 |
|
|
|a 33
|2 sdnb
|
| 084 |
|
|
|a 32
|2 sdnb
|
| 100 |
1 |
|
|a Alhalabi, Obada
|d 1994-
|e VerfasserIn
|0 (DE-588)1193522706
|0 (DE-627)167225941X
|4 aut
|
| 245 |
1 |
0 |
|a Utilizing gene expression profiling, phosphoproteomics and loss-of-function screens to enhance the therapeutic efficacy of dasatinib in glioblastoma
|c vorgelegt von Obada Alhalabi; Doktorvater: Herr Prof. Dr. med. Peter Lichter
|
| 264 |
|
1 |
|a Heidelberg
|c 2022
|
| 300 |
|
|
|a 107 Seiten
|b Illustrationen, Diagramme
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 502 |
|
|
|b Dissertation
|c Ruprecht-Karls-Universität Heidelberg
|d 2023
|
| 546 |
|
|
|a Text in Englisch, Zusammenfassung in englischer und deutscher Sprache
|
| 655 |
|
7 |
|a Hochschulschrift
|0 (DE-588)4113937-9
|0 (DE-627)105825778
|0 (DE-576)209480580
|2 gnd-content
|
| 700 |
1 |
|
|a Lichter, Peter
|d 1957-
|e AkademischeR BetreuerIn
|0 (DE-588)1096366282
|0 (DE-627)856749915
|0 (DE-576)468019049
|4 dgs
|
| 710 |
2 |
|
|a Universität Heidelberg
|e Grad-verleihende Institution
|0 (DE-588)2024349-2
|0 (DE-627)102161488
|0 (DE-576)191769517
|4 dgg
|
| 751 |
|
|
|a Heidelberg
|0 (DE-588)4023996-2
|0 (DE-627)106300814
|0 (DE-576)208952578
|4 uvp
|
| 951 |
|
|
|a BO
|
| 992 |
|
|
|a 20230510
|
| 993 |
|
|
|a Thesis
|
| 994 |
|
|
|a 2023
|
| 998 |
|
|
|g 1193522706
|a Alhalabi, Obada
|m 1193522706:Alhalabi, Obada
|d 50000
|d 51001
|e 50000PA1193522706
|e 51001PA1193522706
|k 0/50000/
|k 1/50000/51001/
|p 1
|x j
|y j
|
| 999 |
|
|
|a KXP-PPN1844450724
|e 432040338X
|
| BIB |
|
|
|a Y
|
| JSO |
|
|
|a {"name":{"displayForm":["vorgelegt von Obada Alhalabi; Doktorvater: Herr Prof. Dr. med. Peter Lichter"]},"language":["eng"],"person":[{"given":"Obada","display":"Alhalabi, Obada","role":"aut","family":"Alhalabi"},{"role":"dgs","family":"Lichter","display":"Lichter, Peter","given":"Peter"}],"recId":"1844450724","physDesc":[{"noteIll":"Illustrationen, Diagramme","extent":"107 Seiten"}],"id":{"eki":["1844450724"]},"corporate":[{"display":"Universität Heidelberg","role":"dgg"}],"title":[{"title_sort":"Utilizing gene expression profiling, phosphoproteomics and loss-of-function screens to enhance the therapeutic efficacy of dasatinib in glioblastoma","title":"Utilizing gene expression profiling, phosphoproteomics and loss-of-function screens to enhance the therapeutic efficacy of dasatinib in glioblastoma"}],"type":{"bibl":"thesis"},"noteThesis":["Dissertation. - Ruprecht-Karls-Universität Heidelberg. - 2023"],"origin":[{"dateIssuedKey":"2022","publisherPlace":"Heidelberg","dateIssuedDisp":"2022"}]}
|
| SRT |
|
|
|a ALHALABIOBUTILIZINGG2022
|
